Handok to Announce Phase 2 Clinical Trial Results of Bile Duct Cancer Chemotherapy Next Month
[Asia Economy Reporter Chunhee Lee] Handok announced on the 20th that it will present the key results of the Phase 2 clinical trial of 'HD-B001A (CTX-009, ABL001)' for cholangiocarcinoma patients, currently under development, as a poster at the Gastrointestinal Cancers Symposium (ASCO GI 2023) of the American Society of Clinical Oncology (ASCO) to be held next month.
HD-B001A is a next-generation anticancer drug developed using bispecific antibody platform technology. Handok holds the rights in Korea through a licensing agreement with ABL Bio. Since last year, Handok has been focusing on cholangiocarcinoma and conducting a domestic Phase 2 clinical trial of HD-B001A. Based on the domestic trial, they are laying the groundwork for expanding HD-B001A into global clinical trials and are also collaborating with Compass Therapeutics on clinical trials in the United States.
This Phase 2 clinical trial was conducted at four domestic institutions, including Seoul National University Hospital, targeting patients with unresectable advanced, metastatic, or recurrent cholangiocarcinoma who had previously received first- or second-line systemic chemotherapy. The treatment regimen combined paclitaxel with HD-B001A.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
At ASCO GI 2023, Handok plans to share plans for Phase 2 and 3 clinical trials of HD-B001A in cholangiocarcinoma patients as well as a Phase 2 clinical trial in colorectal cancer patients. The Phase 2 and 3 trials for cholangiocarcinoma patients will be randomized, open-label clinical trials comparing combination therapy of paclitaxel and HD-B001A versus paclitaxel monotherapy in patients with unresectable advanced cholangiocarcinoma who have received one prior systemic chemotherapy and experienced metastasis or recurrence. The Phase 2 trial for colorectal cancer patients will target patients with colorectal cancer metastasized to 2 to 3 sites.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
